Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that long-term administration of tamsulosin hydrochloride 0.2 mg is effective, safe, and well-tolerated for improving symptoms and quality of life in patients with LUTS of BPH.

This study found that combining tamsulosin with finasteride was the most cost-effective treatment for mild to moderate BPH among the regimens tested.

In this study, dual therapy with tamsulosin and solifenacin significantly improved urinary symptom severity and bladder capacity in BPH patients, but did not alter post-void residual urine volume. This supports using the combination therapy for managing LUTS, especially for storage-related symptoms, in clinical settings.

This study found that prescribing finasteride for two weeks before TURP surgery reduces intraoperative and postoperative blood loss, the rate of blood transfusion, and irrigation fluid usage in patients with BPH.

In this study, Leonuri Herba alkaloids significantly reduced prostate hyperplasia indicators and improved urinary parameters in hormone-induced model rats.

In this study, researchers found that the microRNA miR-1199-5p may reduce the expression of SRD5A2 in benign prostatic hyperplasia tissues, potentially contributing to the failure of 5-α reductase inhibitor therapy in some patients.

This study concluded that qianliekang combined with liuweidihuangwan is a more economical treatment for benign prostatic hyperplasia compared to finasteride plus tamsulosin.

This study reports that saw palmetto may effectively treat benign prostatic hyperplasia symptoms and potentially stimulate hair growth with generally mild side effects.

This study found significant species differences in the enzyme activity and inhibitor affinities of prostatic 5α-reductases from rats, dogs, and humans, with variable potencies for different 3-oxo-4-azasteroid inhibitors across species.

This study demonstrates that patients with benign prostatic hyperplasia have a higher severity and frequency of male pattern baldness compared to a control group.

This study found that keratinocyte growth factor is a potent mitogen in human hyperplastic prostate cells, suggesting it plays an important role in prostate growth by acting in a paracrine manner.

This article reviews the effects of 5 alpha-reductase inhibitors for treating conditions like male pattern baldness and benign prostatic hyperplasia, noting significant DHT reduction but reports no new clinical results.

This study explored how modifying the 8-substituent of 8-bromobenzoquinolinone affects its selectivity in inhibiting both 5 alpha-reductase isozymes in the scalp.

This study in rats suggests that combining the 5 alpha-reductase inhibitor 4-MA with the antiandrogen Flutamide may enhance prostate cancer therapy by additively inhibiting prostatic growth and mRNA levels of androgen-sensitive prostatic binding proteins.

In this study, researchers developed a coamorphous form of tadalafil and finasteride, showing improved solubility and dissolution in vitro, with results successfully translated in vivo in rats. They reported reasonable stability, suggesting this form could serve as a therapeutic alternative to the current marketed combination.

Finasteride reduces the need for prostate surgery but may increase the risk of depression and persistent sexual side effects.

Dutasteride and finasteride have equal safety for treating BPH without increased heart risk.

Dutasteride and finasteride don't raise erectile dysfunction risk.

This review provides an in-depth examination of the efficacy and safety of finasteride and dutasteride, commonly used for treating benign prostatic hyperplasia and male androgenetic alopecia.

This study found that combining dibenyline and finasteride for symptomatic BPH treatment offered modest improvements with fewer additional side effects compared to each drug alone.

5α-reductase inhibitors can reduce prostate cancer risk but may increase high-grade tumors, needing more research.

This paper discusses the effect of dutasteride on prostate cancer detection in men with benign prostatic hyperplasia but provides no new clinical results.

This study found that finasteride use was significantly associated with the reporting of obstructive sleep apnea and insomnia compared to all other drugs in the FAERS database.

This review discusses persistent adverse effects of 5α‐reductase inhibitors, like diminished libido and erectile dysfunction, in some patients and highlights the need for patient discussions before therapy, especially for androgenetic alopecia.

Finasteride helps regrow hair and shrink prostate by reducing DHT, with some sexual side effects.

This review found that 5α-reductase inhibitors are associated with slightly increased rates of sexual dysfunction, gynecomastia, and mood disorders, but the true significance and persistence of these effects remain unclear.

This study suggests that a larger prostate is associated with a higher prevalence of androgenetic alopecia, although the prostate size did not correlate with alopecia severity.

This study found that men aged 50 and older with clinical benign prostatic hyperplasia have a significantly higher prevalence of metabolic syndrome than those without the condition in the UK primary care population.

This study found no difference in male pattern baldness between patients with benign prostate hyperplasia and prostate cancer, and no correlation with serum androgen levels.

Benign Prostatic Hyperplasia may be caused by changes in how the body processes male hormones.